Phase 2 Non-Squamous Clinical Trials
11 recruitingPhase 2
What is a Phase 2 trial?
Phase 2 trials evaluate whether a treatment works for a specific condition and further assess its safety. These studies typically enroll several hundred participants and provide preliminary data on effectiveness.
Showing 1–11 of 11 trials
Recruiting
Phase 2
Testing the Addition of an Anti-Cancer Drug, TRC102, to the Usual Chemotherapy Treatment (Pemetrexed, Cisplatin or Carboplatin) During Radiation Therapy for Stage III Non-Squamous Non-Small Cell Lung Cancer
Stage III Lung Cancer AJCC v8Lung AdenocarcinomaLung Non-Squamous Non-Small Cell Carcinoma+1 more
National Cancer Institute (NCI)42 enrolled34 locationsNCT05198830
Recruiting
Phase 2
Trial Investigating Visugromab and Nivolumab With or Without Docetaxel in 2L Treatment of Participants With Metastatic NSCLC
Metastatic Non-Squamous Non-Small Cell Lung CancerAdult Solid Tumor
CatalYm GmbH131 enrolled15 locationsNCT07246863
Recruiting
Phase 2
Study to Investigate Petosemtamab in Adults With Metastatic Non-Small Cell Lung Cancer
Lung Cancer - Non Small Cell SquamousLung Cancer - Non Small Cell Non-Squamous
Merus B.V.180 enrolled5 locationsNCT07353957
Recruiting
Phase 2
A Study of BL-M07D1 in Combination With Pembrolizumab in Patients With Unresectable Locally Advanced or Metastatic HER2-Overexpressing Non-Squamous NSCLC
Non-squamous Non-small Cell Lung Cancer
Sichuan Baili Pharmaceutical Co., Ltd.80 enrolled1 locationNCT07264816
Recruiting
Phase 2
Trial Investigating Visugromab in Combination With Immunochemotherapy in 1L Treatment of Participants With Metastatic NSCLC
Metastatic Non-Squamous Non-Small Cell Lung CancerAdult Solid Tumor
CatalYm GmbH107 enrolled25 locationsNCT07098988
Recruiting
Phase 2
IBI363 Combined With Chemotherapy or Pembrolizumab Combined With Chemotherapy as Neoadjuvant Therapy in Resectable Stage IB-III Non-Squamous Non-Small Cell Lung Cancer
Resectable Stage IB-III Non-Squamous Non-Small Cell Lung Cancer
Innovent Biologics (Suzhou) Co. Ltd.170 enrolled1 locationNCT07122687
Recruiting
Phase 2
Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL Cancer
Advanced Non-squamous Non-small-cell Lung CancerAdvanced Squamous Non-Small Cell Lung Carcinoma
Genelux Corporation142 enrolled16 locationsNCT06463665
Recruiting
Phase 2
A Study of JS207 (PD-1/VEGF Bispecific Antibody) in Combination With Chemotherapy in Advanced Non-small Cell Lung Cancer
Non-squamous Non-small Cell Lung Cancer
Shanghai Junshi Bioscience Co., Ltd.42 enrolled1 locationNCT06868836
Recruiting
Phase 2
Cadonilimab in Patients (Pts) with Advanced Non-small Cell Lung Cancer (NSCLC)
Stage IVB Lung CancerNon-Squamous
Cancer Institute and Hospital, Chinese Academy of Medical Sciences44 enrolled1 locationNCT06793813
Recruiting
Phase 2
Neo-Bio-ADAURA: a Phase II Study to Evaluate Mechanisms of Resistance to Neoadjuvant Osimertinib
Non-squamous NSCLC
Jair Bar, M.D., Ph.D.20 enrolled2 locationsNCT06206850
Active
Phase 2
SHERLOCK: Phase 2 trial of sotorasib in combination with carboplatin-pemetrexed and bevacizumab-biosimilar as first line treatment for advanced non-squamous non-small cell lung cancer with KRAS G12C mutation
advanced non-squamous non-small cell lung cancer
with KRAS G12C mutation
The University of Sydney52 enrolled13 locationsACTRN12622000973718